KBLB Kraig Biocraft Laboratories Inc.

Kraig Biocraft Laboratories Announces Creation of Production Ready Spider Silk Hybrid: BAM 1

Kraig Biocraft Laboratories Announces Creation of Production Ready Spider Silk Hybrid: BAM 1

ANN ARBOR, Mich., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company"), announces the successful creation of a new recombinant spider silk hybrid. This new two-strain hybrid is the result of the Company's successful program to produce larger and more robust production strains ahead of its Spring production trials. The Company's technology utilizes scientifically enhanced silkworms to produce recombinant spider silk.

This enhanced silkworm hybrid, designated by the Company as BAM 1, is the result of careful selective breeding to maximize both robustness and the ratio of usable silk per cocoon. Based upon its initial evaluation and a comparison of genetics, the Company believes that this new two-strain hybrid is the most efficient spider silk production system produced to date. The finished cocoons were tested for cocoon size and silk yield.

The development of this new hybrid involved the careful selective breeding of the Company's Dragon SilkTM strain with numerous pure commercial production silkworm strains. Once the Company's spider silk traits were bred and stabilized in the commercial strains, a series of cross-mattings were completed to test the results of various pairings.

This new hybrid produces more useable silk per cocoon than previous hybrid pairings and is expected to make the transition from development into operations in the first and second quarters of 2024.  

"This new hybrid will play a key role in our production trials. Our team is currently scaling up production of the two parental lines used to create this hybrid. One of those parental lines is already homozygous for the spider silk gene. The next milestone, which we believe is imminent, will be to establish homozygosity with the second parental strain," said Founder and CEO, Kim Thompson. "The BAM 1 recombinant spider silk hybrid will be the central player in Kraig Labs' spring production trials."

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (), a reporting biotechnology company is the leading developer of recombinant spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward-Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward-looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495



EN
06/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kraig Biocraft Laboratories Inc.

 PRESS RELEASE

Kraig Biocraft Laboratories Deploys Over 700,000 BAM-1 Alpha Productio...

Kraig Biocraft Laboratories Deploys Over 700,000 BAM-1 Alpha Production Hybrids, Achieving Key Milestone in its Aggressive Scale-Up Plan ANN ARBOR, Mich., March 30, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced the successful deployment of more than 700,000 BAM-1 Alpha production hybrids of its previously reported 1,000,000 egg inventory. These silkworms are now in active production. This achievement underscores the Company's continued execution of its previou...

 PRESS RELEASE

Kraig Biocraft Laboratories Increases R&D Capacity, as Project Atlas B...

Kraig Biocraft Laboratories Increases R&D Capacity, as Project Atlas Breakthroughs Creating New Spider Silk Transgenics ANN ARBOR, Mich., March 23, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a significant expansion of its research and development capacity designed to keep pace with rapid progress of its advanced materials initiative, Project Atlas. The Company has expanded its laboratory capabilities, onboarding new scientific personnel and the deploymen...

 PRESS RELEASE

Engineered Silkworms Spin Spider Silk as Biotech Firm Targets Commerci...

Engineered Silkworms Spin Spider Silk as Biotech Firm Targets Commercial Scale DENVER, March 18, 2026 (GLOBE NEWSWIRE) --  -- A biotechnology company developing genetically engineered silkworms says it’s moving toward commercial production of spider silk, a material long sought by researchers for its unusual combination of strength and elasticity. Kraig Biocraft Laboratories (OTCQB: KBLB) deployed one million genetically engineered silkworm eggs across multiple production facilities in Vietnam as part of a Spring scale-up effort that could eventually produce around 10 metric tons of reco...

 PRESS RELEASE

24/7 Market News: Kraig Labs the Bootstrapped Unicorn in the Making

24/7 Market News: Kraig Labs the Bootstrapped Unicorn in the Making DENVER, March 11, 2026 (GLOBE NEWSWIRE) -- -- In technology and biotechnology, “unicorn” status is typically reserved for private companies valued at $1 billion or more; often backed by major venture rounds, institutional syndicates, and aggressive capital deployment strategies. But what happens when a company advances a platform with billion-dollar potential without the backing of Silicon Valley mega-funding? That question is increasingly being asked about Kraig Biocraft Laboratories (OTCQB: KBLB). More than a decade ...

 PRESS RELEASE

Kraig Biocraft Laboratories Targets New Industrial and Defense Biomate...

Kraig Biocraft Laboratories Targets New Industrial and Defense Biomaterials as "Project Atlas" Hits Major Milestone ANN ARBOR, Mich., March 05, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a major milestone in "Project Atlas", the Company's next-generation bioengineering initiative aimed at creating entirely new classes of materials for industrial and defense applications. Kraig Labs first disclosed the existence of Project Atlas on January 19th, 2026, when ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch